Category: Business
GFN Thursday: Dive into 'PEAK' Gaming on GeForce NOW
PEAK, a co-op climbing game, now available on GeForce NOW. Join up to four players, scavenge for food, and ascend
Verona Pharma Soars 20.6% on $10B Merger with Merck
Verona Pharma plc (NASDAQ:VRNA) surged 20.62% to $104.77 per share after news of its $10 billion acquisition by Merck. Merck
5 Strategies to Cut Business Costs and Boost Profitability
Entrepreneurs relish the control of running a business, but economic conditions like inflation can pose challenges. 58% of business owners
Taiwan Semiconductor Manufacturing Company Limited (TSM) Shines as Essential Player in AI Market
Longriver Investment Partners released its “Longriver Partners Fund” second-quarter 2025 investor letter, boasting a 11.7% return for the quarter and
Delta Air Lines Exceeds Expectations in 2Q 2025 Earnings, Shares Soar
Delta Air Lines revised its 2025 profit forecast due to lower demand and flight surplus, but beat summer travel expectations.
The Best Performing Investment Trusts: Private Equity and Technology Lead the Way
The 10 best-performing investment trusts over the past decade include private equity, technology, global large-cap, and US large-cap vehicles. The
Symbotic appoints new CFO to drive future growth
Symbotic Inc. unveils transition plan for new CFO, appointing Izzy Martins to take over from Hibbard on August 9, 2025.
Lantronix partners with investment fund, secures major contract
Lantronix, Inc. (NASDAQ:LTRX) has entered a cooperation agreement with Chain of Lakes Investment Fund, LLC. Under the agreement, James C.
Hyster-Yale's Strategic Realignment to Cut Costs
Hyster-Yale, Inc. (NYSE:HY) is part of the 10 Best Small Cap Robotics Stocks to Buy Now. They announced a strategic
Myomo Aims for $100 Million Revenue Goal by 2028
Myomo, Inc. (NYSE:MYO) is listed as one of the 10 Best Small Cap Robotics Stocks to Buy Now. The company
Knightscope Secures $1 Million in New Contracts, Expanding Reach
Knightscope, Inc. closed $1 million in new contracts on July 2, reflecting strong demand for its products. The company secured
Morgan Stanley Rates Kymera Therapeutics (KYMR) Overweight
Morgan Stanley analyst Judah Frommer initiated coverage of Kymera Therapeutics, Inc. (KYMR) with an “Overweight” rating and a $70 price
Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock to 'Overweight'
Barclays upgraded Ionis Pharmaceuticals (IONS) stock to “Overweight” from “Equal Weight” with a price target of $57, ahead of Tryngolza
Morgan Stanley Rates Disc Medicine (IRON) "Overweight" With $85 PT
Disc Medicine, Inc. (NASDAQ: IRON) receives an “Overweight” rating and $85 price target from Morgan Stanley. Bitopertin’s accelerated approval process
